2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have

Description:,Program Overview:,2022 has been a banner year for patients with pediatric atopic dermatitis (AD) as well as for their parents, families, and healthcare providers. The biologic dupilumab was approved for moderate to severe AD for ages 6 months to 5 years. Adolescents with AD also got new treatment options with approvals of oral systemic and topical JAK inhibitors, upadacitinib and ruxolitinib, respectively. There are also biologics and JAK inhibitors that are now in phase 3 clinical trials for children and adolescents with AD.,Learning Objectives:,Upon completion of this educational activity, participants should be able to:,• Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications,• Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD,Additional details will be posted as soon as information is available.